Roche's Genentech on Tuesday formally petitioned FDA to reconsider its decision to revoke approval of Avastin as a treatment for breast cancer, the New York Times' "Prescriptions" reports. Genentech requested that FDA hold a public hearing to re-examine its decision...
More...